OKYO Pharma has started Phase II trial for OK-101, a potential treatment for neuropathic corneal pain. This innovative drug targets chemerin receptors to address the lack of FDA-approved options. The trial aims to benefit patients suffering from NCP, a condition with limited management strategies.